Allergy Therapeutics originates from a specialist allergy company founded in Devon in 1934. They develop specific immunotherapy or desensitization therapies. These allergy vaccinations are designed to prevent allergy-related conditions rather than merely dealing with the symptoms.

Though the aim is to cure the condition, further 'rescue' treatments may still be needed during times of particularly high pollen. Nevertheless, Allergy Therapeutics states that symptoms should be dramatically reduced. The vaccinations are also designed to act preventatively against the advancement of progressive conditions that can lead to severe asthma.

The company's research and development is focused on developing both treatment and prevention therapies. Their current portfolio of products is based on allergoid (modified allergens), tyrosine depot and MPL adjuvant.

Products

Allergy Therapeutics has developed slow-release depot formulations for allergy vaccines. They use L-tyrosine, a natural amino acid, in vaccine formulations. Their new vaccine product development frequently involves the use of MPL® (Monophosphoryl lipid A), an immunological adjuvant that Allergy Therapeutics has licensed from Corixa, a US biotechnology company. MPL® has demonstrable T helper cell activity and a non-toxic profile in animals and humans.

They are currently developing a range of orally administered allergy vaccines comprising common allergens combined with MPL®. These vaccines are designed to overcome the need for injections, allowing self-administration and removing dependence on clinically supervised administration.

allergytherapeutics.com